Nirogacestat Dihydrobromide is an orally administered gamma-secretase inhibitor used in the treatment of progressing desmoid tumors, where it functions by suppressing Notch signaling to inhibit tumor proliferation.… Read more



Nirogacestat Dihydrobromide is an orally administered gamma-secretase inhibitor used in the treatment of progressing desmoid tumors, where it functions by suppressing Notch signaling to inhibit tumor proliferation. This category provides essential materials for the analytical characterization and quality control of this therapeutic agent, including high-purity reference standards of the active pharmaceutical ingredient. Laboratories utilize these compounds for comprehensive impurity profiling, ensuring that both pharmacopeial and non-pharmacopeial impurities are accurately identified and quantified during method validation and stability testing. Additionally, stable isotope labelled versions, such as deuterated analogues, are available to serve as internal standards in mass spectrometry-based assays. By supporting precise pharmacokinetic studies and regulatory compliance testing, these reference materials facilitate the rigorous assessment of Nirogacestat Dihydrobromide throughout its development and manufacturing lifecycle.